Polymers 17 (11), 1538
Twarda-Clapa A, Olczak A, Bialkowska AM, Koziolkiewicz M
The A phase constituent is added proper container, and heating in water bath to 70 is to 80 .B phase constituent (not comprising the carbomer dispersion) is added proper container and mixing.Also the C phase constituent is added in the proper container, heating in water bath to 70 is to 80 subsequently.CoQ10 21% concentrate of E phase is placed proper container, use in 50 to 60 of fusings down of water-bath.Blending constituent is to guarantee uniformity in case of necessity.Subsequently the carbomer dispersion is added proper container (agitator tank), under blended condition, be heated to 70 to 80 .In blending constituent, the B phase constituent is added to the content of agitator tank, keep this temperature simultaneously.Continue to mix and the homogenize content.Close agitator subsequently, yet continue homogenize.When continuing homogenize, with the titanium dioxide adding agitator tank of D phase.Open agitator then, mixing and further homogenize content are until fully all even scatter fully (inspection color).Stop homogenize subsequently, batch is cooled to 50 to 60 .Close agitator subsequently, CoQ10 21% concentrate that melts is added to agitator tank.Open agitator subsequently, mixing/recirculation content is pure and even until dispersion.Make the content of agitator tank be cooled to 45 to 50 subsequently.Subsequently content is transferred to store in the proper container until unpacking and gets thing
The EVACS study demonstrated that the use of evolocumab immediately after an ACS was associated with significant LDL-C reduction as early as after 3 days (mean concentration 1.3 mmol/l) and below 1 mmol/l (40 mg/dl) after 47 days, as compared with the control group
L-Carnitine+L-Arginin eurhovital
